No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRNA Moderna
- 165.730
- +1.720+1.05%
Trading May 24 10:53 ET
63.51BMarket Cap-10630P/E (TTM)
170.470High162.000Low2.02MVolume164.090Open164.010Pre Close335.96MTurnover0.58%Turnover RatioLossP/E (Static)383.24MShares170.47052wk High4.96P/B57.87BFloat Cap62.55052wk Low--Dividend TTM349.18MShs Float497.490Historical High--Div YieldTTM5.16%Amplitude11.540Historical Low166.071Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Moderna Options Spot-On: On May 23rd, 74,493 Contracts Were Traded, With 392.39K Open Interest
On May 23rd ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 74,493 options for the day, of which put options accounted for 44.28% of the total transactions, and call
8 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
Moderna on Track for Highest Close Since February 2023 -- Data Talk
Moderna, Inc. (MRNA) is currently at $164.31, up $0.98 or 0.6% --Would be highest close since Feb. 17, 2023, when it closed at $166.60 --Currently up 11 of the past 12 days --Currently up nine cons
Heard on the Street: Moderna Got a Boost From Bird Flu, but Don't Count Your Chicks -- WSJ
By David Wainer Vaccine stocks are back in vogue, at least for now. Moderna, BioNTech, CureVac and Novavax have added billions of dollars in combined market capitalization gains in recent days after
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Moderna Options Trading: A Deep Dive Into Market Sentiment
Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled t
Comments
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
3
1
$Moderna(MRNA.US$ yeah I thought this company made money?
3
📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : Review extended to 8/14/24 🤔
⇒ YORV...
10
$Novavax(NVAX.US$ $Moderna(MRNA.US$ Moderna and Novavax Hope for Early Launch of This Year's Covid-19 Shots, Despite FDA Delay -- Barrons.com
Barron's· 3 mins ago
U.S. vaccine makers say that the Food and Drug Administration's delay in designing this fall's Covid-19 vaccines shouldn't push back the rollout of the shots, amid rapid shifts in the genetic makeup of the virus.
Vaccine makers Moderna and Novavax are hoping for an August rollout this year, earlier than last year's late Septembe...
Barron's· 3 mins ago
U.S. vaccine makers say that the Food and Drug Administration's delay in designing this fall's Covid-19 vaccines shouldn't push back the rollout of the shots, amid rapid shifts in the genetic makeup of the virus.
Vaccine makers Moderna and Novavax are hoping for an August rollout this year, earlier than last year's late Septembe...
$Novavax(NVAX.US$
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
👉 Key Highlights:
📍 Novavax's shares jump 120% in premarket trading after announcing a deal with Sanofi.
📍 Partnership to co-commercialize Covid vaccine and develop combination flu shots.
📍 Sanofi to make an upfront payment of $500 million to Novavax, with potential for up to $700 million more.
📍 Deal includes royalties and up to $200 million in additional milestones.
📍 Sanofi acquires less than ...
3
3
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Srav Reddy : Any idea $Akoya Biosciences (AKYA.US)$ drop 35% this week